세포 사멸 분석: 세포 독성 능력의 크롬 방출 분석
View the full transcript and gain access to JoVE Science Education videos
Q1: What is the chromium release assay and why is it used to measure immune cell function?
The chromium release assay quantifies the cytotoxic potential of immune cells like T cells and NK cells by measuring their ability to kill target cells. Target cells are labeled with radioactive chromium-51, co-cultured with effector cells, and cell lysis releases the chromium into the supernatant. A gamma counter measures the radioactivity, providing a quantifiable output of target cell death that reflects immune cell activation and potency.
Q2: How does chromium-51 labeling enable detection of target cell death?
Chromium-51 is a radioactive isotope that is rapidly taken up by target cells and nonspecifically labels cellular proteins. When effector cells induce lysis and loss of membrane integrity in target cells, the labeled chromium is released into the culture supernatant. The radioactive chromium spontaneously undergoes gamma radiation decay, which is detected and quantified using a gamma counter to determine the extent of cell death.
Q3: What is the role of serial dilutions in the chromium release assay protocol?
Serial dilutions create a range of effector cell concentrations in the assay plate, allowing researchers to establish the relationship between effector cell number and target cell killing. By progressively diluting effector cells across plate rows, the assay generates multiple data points showing how cytotoxic activity varies with different effector-to-target cell ratios, enabling comparison of immune cell potency under different conditions.
Q4: Why are control wells essential in the chromium release assay?
Control wells serve critical functions: row A contains target cells alone to measure spontaneous chromium release without effector cells, and row H contains 1% NP-40 detergent to lyse all target cells and determine total counts per minute. These controls establish baseline and maximum chromium release values, enabling calculation of percent specific lysis by accounting for background radioactivity and normalizing experimental results.
Q5: How is percent specific lysis calculated from chromium release assay data?
Percent specific lysis is calculated using the formula: (experimental CPM minus spontaneous CPM) divided by (maximum CPM minus spontaneous CPM), then multiplied by 100. Counts per minute from triplicate wells are averaged, and spontaneous release from control wells is subtracted from experimental values. This calculation normalizes results and allows direct comparison of cytotoxic activity between different effector cell populations or treatment conditions.
Q6: What safety precautions are necessary when working with chromium-51?
Chromium-51 requires dedicated laboratory space with ample lead shielding for safe storage and handling during all steps. A Geiger counter with a pancake probe must be available to survey for contamination. Proper signage indicates where radioactive samples are kept, and all radioactive materials must be labeled with radioactive tape. Appropriate personal protective equipment, including lab coat and gloves, is essential when handling chromium-51.
Q7: How does CpG stimulation affect the cytotoxic capacity of peripheral blood mononuclear cells?
CpG-stimulated peripheral blood mononuclear cells demonstrate significantly enhanced killing of target cells compared to unstimulated cells, particularly as the effector-to-target cell ratio increases. In the assay example, CpG stimulation was necessary for observed increases in target cell lysis, indicating that immune cell activation through CpG stimulation is required to achieve robust cytotoxic responses against melanoma cells.